JenaValve Trilogy successfully implanted for the first time in Asia at Queen Elizabeth Hospital, Hong Kong. 

 Enrollment commenced for the TaurusTrio™ multi-center clinical trial in China for aortic valve regurgitation treatment. 

 MonarQ TTVR System achieved successful first-in-human implantation in the U.S. 

 HighLife multi-center clinical trial investigator coordination meeting held at the Chengdu Valve Conference.

 Spearheaded the establishment of the Suzhou Interventional Medical Technology Innovation Consortium. 

 DCwire™ microguidewire and NRCoil™ detachable coils approved for market launch in the neurointerventional field. 

 Global headquarters officially inaugurated.